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Abstract Hemicrania continua (HC) is a primary head-
ache disorder characterized by a continuous, unilateral
headache that varies in intensity, waxing and waning
without disappearing completely. Ipsilateral cranial auto-
nomic features and response to indomethacin are essential
features for the diagnosis of HC. We hereby, describe three
patients with the clinical phenotypes of HC in whom
response to indomethacin was either incomplete or not
sustained. We also review the literature especially for the
presence of indomethacin response and ipsilateral cranial
autonomic features.
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Introduction
Hemicrania continua (HC) is an uncommon primary
headache syndrome. The syndrome HC presents three
characteristics: (1) strictly unilateral continuous pain
(moderate, fluctuating), (2) at least one ipsilateral cranial
autonomic feature, and (3) complete response to thera-
peutic doses of indomethacin [1]. However, as HC is a
relatively recently described entity, its natural history is
still being determined. Knowledge regarding HC has rap-
idly changed over years. Even the diagnostic criteria of HC
have been repeatedly modified and revised over the last
10 years [1–3]. All the three characteristic features are
essential to satisfy the International Headache Society
(IHS) criteria for HC. However, the criteria proposed by
other authors are more accommodating [2]. If we strictly
adhere to the IHS criteria for HC, many cases reported
earlier may not be labeled as HC. We here, describe three
patients with the clinical features of HC in whom response
to indomethacin was either incomplete or not sustained.
Case reports
Case 1
A 30-year-old man presented with a 4-month history of
continuous right-sided headache. The pain was maximal in
the right supraorbital and retro-orbital areas radiating to the
temporoparietal and maxillary regions. The pain was
described as a constant ache of moderate severity with
superimposed exacerbations of severe to excruciating pul-
sating pain lasting 2–60 min. Exacerbations occurred 3–20
times in a day, and were associated with ipsilateral con-
junctival injections, lacrimation and rhinorrhea in about
50% of the attacks. The patient never developed aura,
nausea, photophobia, phonophobia or restlessness (agita-
tion) during the exacerbations. Nocturnal attacks were
common. There were no precipitating or aggravating fac-
tors. The patient had no prior history of headache or head
trauma. Family history for headache was negative. Past
treatments with paracetamol, ibuprofen, tramadol, ami-
triptylin, and propranolol were without benefit.
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Physical examinations and investigations [including
magnetic resonance imaging (MRI) brain] were normal.
Diagnosis of HC was made. He showed complete response
to indomethacin at the dose of 75 mg tid. The patient had
never felt such type of improvement (either spontaneously
or with any drugs) since the beginning of his clinical
presentation. However, response persisted only for 2 days
and the headache recurred with the same intensity and
frequency. Indomethacin was gradually increased up to
150 mg tid. However, the patient did not feel any relief in
his symptoms. Further trials with topiramate and gaba-
pentine were without any benefit. The patient lost to
follow-up after 6 weeks.
Case 2
A 46-year-old female presented with a 5-year history of
continuous right-sided headache with superimposed exac-
erbations. The continuous pain was dull, of moderate
severity, and maximal in the retro-orbital and infraorbital
areas radiating to the entire hemicranium (including teeth
and gums). The exacerbations, described as throbbing and/
or stabbing type of pain, were associated with ipsilateral
cranial autonomic features (especially ptosis and conjunc-
tival injection) in about one-third of the attacks.
Exacerbations occurred 10–20 times daily, lasting 10 min
to 2 h.
Prior treatments with propranolol, aspirin, ibuprofen,
topiramate, sodium valproate, amitryptiline, gabapentine
were without benefit. Dental extraction was done twice,
suspecting that pain was of dental origin. The patient was
extensively investigated for 5 years. She got done a MRI of
the brain and orbit two times, which revealed no abnor-
mality. General and neurological examinations were
normal. A diagnosis of HC was made and indomethacin
was started at a dose of 25 mg tid.
No response was noted at this dose. It was gradually
increased to 100 mg tid. With this dose, she noted marked
(but incomplete) improvement in 7 days. Her background
headache subsided completely. The frequency of attacks
decreased to 1–3 per day. The intensity and duration of
attacks also reduced markedly. Further, increase of the
dose (up to 150 mg tid) did not provide any additional
benefit. The patient developed pain abdomen after about
15 days and indomethacin was stopped. However, symp-
toms recurred on the same day with the same intensity,
duration, and frequency. Indomethacin was reinstituted
after 2 weeks with gastric protection. The dose was grad-
ually increased up to 100 mg tid. The patient again showed
partial improvement. There was only a mild background
headache (at times the background headache also disap-
peared). In next 2 months of follow-up, she had 1–2
episodes of exacerbation in a day.
Case 3
A 29-year-old female presented with a 6 months history of
continuous left-sided headache. The pain was described as
a steady ache of mild to moderate severity with superim-
posed exacerbations of throbbing pain, recurring 1–3 times
daily. Exacerbations lasted from 10 min to 2 h and were
associated with ipsilateral conjunctival injection, lacrima-
tion, nausea, photophobia, and phonophobia. The pain was
maximal in the left orbit radiating to the temporoparietal
and maxillary areas. There were occasional nocturnal
attacks. No triggering factors were noted. Family history
for headache and history of head trauma were negative.
Prior treatments with propranolol, amitriptyline, naproxen,
and paracetamol were ineffective. Neurological examina-
tion, routine hematological, biochemical examinations, and
MRI of the brain were normal. Treatment with indometh-
acin 25 mg tid was ineffective. Gradually increasing the
dosage to 100 mg tid produced incomplete improvement.
Her background headache reduced in intensity (However, it
persisted in a continuous pattern). The frequency of exac-
erbations reduced to 1–2 episodes in a week. However,
the intensity of exacerbations (severe, disturbing routine
activities) and the duration (10 min to few hours) were the
same, as she had been suffering previously before the
introduction of indomethacin. After 6 weeks of introduc-
tion of indomethacin (100 mg tid), we gave IV MPS
(500 mg) daily in normal saline for 3 days with gastric
protection. We asked the patient to continue indomethacin
in the same dose (100 mg tid). The background headache
subsided completely on the first day. In the next 3 months,
she had no background headache, nor any exacerbation.
Hence, we tapered the dose of indomethacin. Tapering
further (below 50 mg tid) resulted in the reappearance of
the background headache and the exacerbations.
Discussion
The clinical features and indomethacin-responsiveness of
HC were first described by Medina and Diamond. The term
‘‘hemicrania continua’’ was coined by Sjaastad and Spier-
ings [4], and considered it as an indomethacin-responsive
headache.
According to the present diagnostic (IHS) criteria except
the one stating that a complete and persistent response to
therapeutic doses of indomethacin is a must, all three of our
cases presented phenotypically as HC. The clinical phe-
notype of HC overlaps with that of migraine and trigeminal
autonomic cephalalgias (TACs). The frequencies of exac-
erbations match with paroxysmal hemicrania (PH) in cases
1 and 2, and with cluster headache (CH) in patient 3. The
duration and frequency of exacerbations are not defined in
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the HC criteria. However, the frequency may vary from 20
attacks per day to few attacks in a week [5]. Therefore, the
background headache is the most important feature to
differentiate HC from TACs (as paroxysmal hemicrania
and even few cases of cluster headache show response to
indomethacin) [6]. Although, presence of inter ictal
(background) pain in the patients with PH and CH may
further complicate the diagnosis of HC [7]. Presence of
moderate background pain is the most important point to
differentiate HC with PH and CH [5, 8]. Newman et al. [5]
commented ‘‘If the patient or the doctor focuses on the
painful exacerbations with autonomic features and fails to
consider the continuous, moderate background pain, HC
may be mistaken for cluster headache’’, and probably PH.
The background headache was moderate in all the three
patients.
None of our patients fulfilled the criteria of migraine.
Frequent attacks of migraine (of smaller duration) in a day
were not in favor of migraine. Other differential diagnosis
of HC may include supraorbital neuralgia, cervicogenic
headache, unilateral tension type headache, atypical facial
pain, and temporomandibular joint pain [9]. However,
continuous background pain and periodic exacerbations
especially in retro-orbital areas, and autonomic features are
against the diagnosis of almost all the above-mentioned
differential diagnosis. Case 1 showed complete response to
indomethacin, but it persisted only for 2 days. Case 2
showed partial response even at the dose of 150 mg tid.
Case 3 showed incomplete response at the dose of 100 mg
tid. However, a 3 days course of IV MPS provided a
complete response. Recently, two patients of HC were
reported who showed complete response to IV MPS
(without concomitant use of indomethacin) [10]. However,
case 3 was also receiving indomethacin during the
administration of IV MPS. The temporal relation of the
disappearance of headache and the administration of IV
MPS suggests that MPS was pivotal in the disappearance of
headache. However, recurrence of headache after 3 months
on withdrawal of indomethacin suggests that the headache
was responsive to indomethacin. Probably, IV MPS facil-
itated the effect of indomethacin in the early part of the
treatment.
The variability in time interval between indomethacin
administration and response (few hours to 10 days) and
variability in indomethacin requirement with time may be
the causes of unresponsiveness in few patients of indo-
methacin unresponsive HC [11]. There is suggestion to
give indomethacin parenterally (INDOTEST) to avoid such
problem [12]. However, injectable indomethacin is not
available in every country. The maximum dose and dura-
tion of indomethacin in our patients were: 150 mg tid for
6 weeks (case 1), 150 mg tid for 2 weeks (case 2), and
100 mg tid for 6 weeks (case 3). Therefore, the possibility
of use of suboptimal dose or the possibility of delayed
response does not exist in our patients.
Sjaastad and Spierings [4] in their original article of HC
comment, ‘‘cases unresponsive to indomethacin but
otherwise corresponding entirely to the present individuals
may well be discovered in the future’’. However, they
failed to find such patients and later on made a comment,
‘‘…a continuous, unilateral headache without response to
indomethacin is not hemicrania continua’’ [13]. However,
many other authors accepted the possibility of occurrence
of indomethacin-resistant HC and, diagnostic criteria have
been proposed that accommodate both indomethacin-
responsive and indomethacin-resistant patients who fit the
clinical phenotype [2, 3, 9]. Pareja et al. [9] proposed the
term ‘‘hemicrania generis incerti’’ for the indomethacin-
resistant HC. Goadsby and Lipton [11] suggested the term
hemicrania continua (possible) for the patients who
fulfilled criteria except the indomethacin response. A
complete and persistent response to indomethacin was
included as a pre-requisite criterion for the diagnosis of HC
by the classification criteria of the IHS in 2004 [1]. Many
cases (at least 13) have been reported (before 2004), where
typical cases of HC did not respond to indomethacin [14–
18]. Kuritzky [15] reported four patients who otherwise
met clinical criteria for HC yet failed to respond to treat-
ment with indomethacin. However, the maximum dosage
used was 100 mg of indomethacin daily, and the possibility
remains that higher doses may have provided benefit.
Pascual [14] reported another patient unresponsive to
225 mg/day of indomethacin. Wheeler [16] reported six
patients of HC who did not show response to indomethacin.
Besides these, there are many other cases, where response
to indomethacin was not complete or sustained [17, 18].
However, there is no case report of indomethacin-resistant
HC (or HC like headache) in the literature after 2004.
Nevertheless, we found at least two cases in the literature,
where response to indomethacin was not complete or per-
sistent [19, 20]. The sudden scarcity of the indomethacin-
resistant HC in the literature (after 2004) may be because
of under (or no) reporting of such type of headache, as it is
difficult to classify HC like headache unresponsive to
indomethacin. Newman et al. [21] wrote, ‘‘We too have
observed patients with headaches clinically indistinguish-
able from HC that do not respond to maximum doses of
indomethacin. We do not know how to classify these
unusual patients. They may be a treatment-refractory sub-
group of HC patients’’. However, on review of the
literature we did not find any such patients (indomethacin-
resistant HC) by Newman in the literature. This observa-
tion further suggests about under (or no) reporting of such
type of headache. Response to indomethacin was an
inclusion criterion in the observation or studies even before
2004 [22, 23]. Therefore, the possibility of the under
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reporting of HC like headache exists even before the
publication of IHS classification.
As response to indomethacin is an essential feature for
the diagnosis of HC, physicians do not take trials of other
drugs (especially in the early part of the treatment).
Although, various drugs are reported effective (usually in
isolated cases) in the patients with HC, no drug (other than
indomethacin) is found consistently effective [24]. This
creates a problem for the patient (and the treating physi-
cian). Case 1 lost to follow-up, as we could not provide any
relief to him.
At least one of the autonomic features (ipsilateral to the
side of pain) during the exacerbations is one of the essential
features in the IHS diagnostic criteria. According to this
criterion, many of the patients described in the literature
cannot be labeled as (at least definite) HC. Nine patients
(out of the 34) (26%) of Peres et al. [23] series did not
show any autonomic features. The authors reviewed the 41
other cases in literature, and noted the absence of auto-
nomic features in 15 cases (37%). Three patients (out of
10) of Bigal et al. [25] series did not have any autonomic
features. This observation raises the question that how to
classify a patient with HC like headache who shows a
response to indomethacin, but does not have autonomic
features. Can we classify these cases as HC? Again, we did
not find any single case report of HC without autonomic
features in the literature after publication of the IHS clas-
sification (for HC). This again suggests under (or no)
reporting of such type of cases, as it is difficult to classify
such type of patients according to present IHS
classification.
Our case reports and review of the literature suggest that
there is a subset of patients with clinical phenotype of HC,
who do not satisfy all features of the IHS diagnostic cri-
teria. Bigal et al. [25] comment ‘‘…it seems somewhat
exaggerate to consider that HC not responsive to indo-
methacin does not exist’’. We suggest a more inclusive set
of criteria, as proposed by Goadsby and Lipton [2], where
either indomethacin-responsiveness or the presence of one
cranial autonomic feature is sufficient to make the diag-
nosis of HC. Hemicrania continua (possible), as suggested
by Goadsby and Lipton [11], may be another way to
classify such types of patients. The remarkable response of
indomethacin in patients with HC suggests that indo-
methacin probably act on a very specific point in HC
pathophysiology. Thus, indomethacin-resistant HC mean a
headache that lacks this indomethacin specific site of
action. Therefore, the possibility of an independent disor-
der (clinically similar to HC) cannot be ruled out. The
study on pathophysiology of both types of headache (i.e.
HC and HC like headaches resistant to indomethacin) will
help in solving the problem. However, until the under-
lying pathophysiology of HC is understood, it will be better
to use more accommodating type of criteria for clinical
purpose (as proposed by Bigal et al.) [26].
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